Insulet today celebrates the grand opening of a 400,000-square-foot manufacturing facility in Malaysia.
Takeaway Points
- Insulet celebrates the grand opening of a 400,000-square-foot manufacturing facility in Malaysia.
- The new manufacturing facility is situated on the southern end of the Malay Peninsula, just north of Singapore.
- The United States Ambassador to Malaysia, Edgard D. Kagan, and members of the United States Embassy attended the ceremony.
Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, said on Wednesday that it hosting a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia.
The new manufacturing facility is situated on the southern end of the Malay Peninsula just north of Singapore, and is twice the size of Insulet’s highly automated manufacturing facility in Acton, Massachusetts, the company said.
Jim Hollingshead, Insulet President and Chief Executive Officer, said in a comment that the new manufacturing facility in Malaysia will help their customers have undisturbed access to their products.
“Insulet’s remarkable growth is driven by our market-leading Omnipod 5, the first and only tubeless automated insulin delivery system in the U.S. Our new state-of-the-art manufacturing facility in Malaysia positions us strategically to stay ahead of the huge demand for Omnipod, ensuring our customers have uninterrupted access to our products from this thriving region with great talent,” Jim said.
YB Lee Ting Han, Johor State Investment, Trade and Consumer Affairs Committee Chairman, in a comment congratulated the company for finishing the construction of the facility before time.
“We congratulate Insulet on completing construction ahead of schedule. The manufacturing facility is up and running with a local workforce that has been upskilled and trained. This investment by Insulet will have a profound impact on the local economy for many years to come as they grow globally,” said YB Lee.
According to Insulet, United States Ambassador to Malaysia Edgard D. Kagan and members of the United States Embassy attended the ceremony, and presently, more than 350 full-time Insulet employees work at the new facility with plans to grow to more than 1,000 in the coming years, part of a $200 million investment in the area.
About Insulet Corporation
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod ® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
